Following yesterday’s approval of HIV drug Selzentry, Pfizer chose to issue a statement regarding its clinical pipeline. The company announced that it has 47 active programs in its Phase II R&D pipeline—the largest in its history—and contends this will triple the company’s Phase III portfolio by 2009. “The growth of our Phase II cohort is encouraging progress toward meeting our target for our Phase III portfolio by 2009,” said Pfizer’s chairman and chief ex...